Taisho Pharmaceutical Co., Ltd.

Nissan Chemical Industries Limited

Kumi Abe

Xiang-Min Sun

Hiroshi Ohta

Shuji Yamamoto

Yuko Araki

Kazunari Sakagami

Akito Yasuhara

Minoru Moriya

Tsuyoshi Shibata

Takaaki Ishii

Toshio Nakamura

Masato Hayashi

Taketoshi Okubo

Toshihito Kumagai

Yoshinori Sekiguchi

Hiroki Urabe

Takanori Shimizu

Daisuke Wakasugi

Yoshihisa Shirasaki

Tomoko Ishizaka

Youichi Shimazaki

Yuri Amada

Shigetada Sasako

Takayuki Nagatsuka

The present invention relates to novel compounds of formula [I] or pharmaceutically acceptable salts thereof: The compounds of the present invention are useful in the prevention or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, spasm, tremor, pain, Parkinson's disease, attention deficit hyperactivity disorder, bipolar disorder, eating disorder, or sleep disorders, which is based on the glycine uptake-inhibiting action.

Glycine transporter-inhibiting substances

The present invention aims to provide novel compounds of formula [I] or pharmaceutically acceptable salts thereof that are based on a glycine uptake inhibiting action and which are useful in the prevention or treatment of such diseases as schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, specific phobia, acute stress disorder, etc.), depression, drug addiction, spasm, tremor, pain, and sleep disorder: 

Glycine transporter inhibiting substances

The present invention aims to provide novel compounds of formula [I] or pharmaceutically acceptable salts thereof that are based on a glycine uptake inhibiting action and which are useful in the prevention or treatment of such diseases as schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsory disorder, social anxiety disorder, posttraumatic stress disorder, specific phobia, acute stress disorder, etc.), depression, drug addiction, spasm, tremor, and sleep disorder: 

Disclosed is an aminopyrrolidine compound represented by the formula [I] or a pharmaceutically acceptable salt thereof. The compound or the salt is useful as a prophylactic/therapeutic agent for mode disorder such as depression, anxiety disorder, anorexia, cachexia, pain and drug dependence, whose action relies on the MCreceptor antagonistic effect.

Aminopyrrolidine compound

Growing community of inventors

Toshima-ku, Japan

Kumi Abe